Capricor Sues Distributor NS Pharma Over "Fatal Flaw" in Deramiocel Agreement, Seeks Rescission
Summary
Capricor Therapeutics has filed a lawsuit against its exclusive U.S. distributor, NS Pharma, alleging a fundamental pricing flaw and material breaches in their Deramiocel distribution agreement, seeking rescission and direct distribution rights.
Key Events
-
Lawsuit Filed Against Distributor
Capricor initiated legal action against NS Pharma/Nippon Shinyaku in New Jersey Superior Court on May 7, 2026.
-
Distribution Agreement Flaw Alleged
The lawsuit alleges a "fundamental pricing flaw" in the January 2022 Commercialization and Distribution Agreement for Deramiocel, making commercialization economically unviable due to federal Medicare reimbursement structures.
-
Breach of Contract Claims
Capricor claims NS Pharma materially breached the agreement by failing to adequately prepare for Deramiocel's commercial launch, including pausing preparations after a prior FDA Complete Response Letter (CRL) in July 2025.
-
Seeking Rescission and Direct Rights
Capricor is seeking to rescind the agreement, obtain declaratory judgment for direct distribution rights, and secure preliminary injunctive relief.
Analysis
This 8-K details a critical lawsuit filed by Capricor Therapeutics against its U.S. distributor, NS Pharma/Nippon Shinyaku, seeking to rescind their Commercialization and Distribution Agreement for Deramiocel, its lead Duchenne muscular dystrophy (DMD) therapy. The lawsuit alleges a fundamental pricing flaw, particularly concerning Medicare reimbursement, which renders the agreement economically unviable for both parties. Capricor also claims NS Pharma materially breached the agreement by failing to prepare for the commercial launch, including going "pencils down" on preparations after a prior FDA Complete Response Letter (CRL) was issued in July 2025. Despite Deramiocel's positive Phase 3 results and a new PDUFA date of August 22, 2026, the company states NS Pharma's inaction and an unacceptable proposal to cede control of the product forced this legal action. This dispute creates significant uncertainty around the commercialization pathway for Capricor's most advanced product, potentially delaying patient access and impacting future revenue.
At the time of this filing, CAPR was trading at $30.70 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $2B. The 52-week trading range was $4.30 to $40.37. This filing was assessed with negative market sentiment and an importance score of 9 out of 10.